ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0085297 | Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA. | Immunoglobulins, IV|Intravenous Antibodies|IV Immunoglobulins|intravenous immunoglobulin|Intravenous Immunoglobulins|Intravenous Immunoglobulin|Intravenous IG|IGIV|intravenous immunoglobulins|IVIG|Immune Globulin|IV immunoglobulin|GLOBULIN,IMMUNE (IV)|Gamma Globulin Therapy|IVIg|IVIG Therapy|Intravenous Immune Globulin|Immune globulin IV|immune globulin intravenous|Immune Globulin Therapy|Gamma Globulin|immune globulin IV|Antibodies, Intravenous|Intravenous Immunoglobulin Therapy|Immune Globulin, Intravenous|immune globulin, intravenous|Immunoglobulins, Intravenous | immunoglobulins, intravenous |
C0010592 | A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). | Cyclosporine-containing product|cyclosporin a|Ciclosporin|Ciclosporinum|cyclosporin A|ciclosporins|Ciclosporin-containing product|Cyclosporin a|Ciclosporina|Ciclosporin A|Ciclosporin (substance)|cyclosporine|ciclosporin|cyclosporin|Ciclosporine|CYA - Cyclosporine A|Product containing ciclosporin (medicinal product)|Cyclosporin|cycloSPORINE|CYCLOSPORINE|CyA|cyclosporine a|CsA|CYSP|CYA|CYA - Ciclosporin A|Cyclosporine|Cyclosporine Modified|CSA - Ciclosporin A|CSA - Cyclosporine A|Cyclosporine A|Cyclosporin A | cyclosporine |
C0238061 | null | SUBACUTE IDIOPATHIC POLYNEURITIS|RELAPSING GUILLAIN BARRE|CHRONIC GUILLAIN BARRE | CHRONIC INFLAMMATORY POLYNEUROPATHY |
C0007787 | Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6) | Transient ischemic attack|ischemic attack transient|TIA (Transient Ischemic Attack)|Transient cerebral ischemia|attack ischemic transient|transient cerebral ischemic attack|TIA, Brain|TIA|TIA - Transient ischaemic attack|Temporary cerebral dysfunction, vascular|tias|transient cerebral ischemia|T.I.A.|tia brain|Attack, Transient Ischemic|Transient ischaemic attack|STROKE, TEMPORARY|tia|transient ischemic attack|transient ischaemic attack|Transient cerebral ischaemia|Ischemic Attack, Transient|Brain TIA|TRANSIENT ISCHEMIC ATTACKS|Ischemic Attacks, Transient|Transient Ischemic Attacks|Temporary cerebral vascular dysfunction|Transient ischemic attacks|TIAs (Transient Ischemic Attack)|brain tia|Transient ischemic attack (disorder)|transient ischemic attack (TIA)|Attacks, Transient Ischemic|Transient Ischemic Attack|transient ischaemic attacks|attacks ischemic transient|TRANSIENT ISCHEMIC ATTACK|Mini stroke|transient ischemic attacks | Transient Ischemic Attack |
C1514474 | A situation or condition, or a characteristic of a patient, that can be used to estimate the chance of recovery from a disease or the chance of the disease recurring (coming back). | Factor, Prognostic|General Prognostic Factor|Prognostic Factor|Factors, Prognostic|Prognostic/Survival Factor|prognostic factor | Prognostic Factors |
C0014099 | The excision of the thickened, atheromatous tunica intima of a carotid artery. | Carotid endarterectomy|Carotid thromboendarterectomy|CEA - Carotid endarterectomy|Carotid endarterectomy (procedure)|endarterectomy carotid|CAROTID ENDARTERECTOMY|Carotid Endarterectomy|Carotid endarterectomy, NOS|carotid endarterectomy|Endarterectomy, Carotid|Carotid Endarterectomies|carotid artery endarterectomy|carotid endarterectomies|carotid thromboendarterectomy|Carotid thromboendarterectomy, NOS|Endarterectomies, Carotid|Thromboendarterectomy, carotid|Endarterectomy, carotid | Carotid Endarterectomy |
C0007282 | Narrowing or stricture of any part of the CAROTID ARTERIES, most often due to atherosclerotic plaque formation. Ulcerations may form in atherosclerotic plaques and induce THROMBUS formation. Platelet or cholesterol emboli may arise from stenotic carotid lesions and induce a TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; or temporary blindness (AMAUROSIS FUGAX). (From Adams et al., Principles of Neurology, 6th ed, pp 822-3) | Artery Narrowing, Carotid|Stenoses, Carotid Artery|Narrowing of carotid artery|carotid artery narrowing|Carotid Artery Stenoses|arteries carotid stenosis|Carotid Artery Stenosis|Narrowing, Carotid Artery|carotid stenoses|Narrowings, Carotid Artery|stenosis carotid|stenosis carotid artery|carotid artery stenosis|Carotid Artery Narrowing|artery carotid stenosis|arteries carotid narrowing|Carotid Stenoses|Carotid Artery Narrowings|Stenosis, Carotid|carotid stenosis|Carotid stenosis|CAROTID STENOSIS|Carotid artery narrowing|artery carotid stenosi|Carotid artery stenosis (disorder)|Stenoses, Carotid|Stenosis, Carotid Artery|Carotid artery--Stenosis|Artery Stenoses, Carotid|Artery Stenosis, Carotid|Carotid artery stenosis|Artery Narrowings, Carotid | Carotid Stenosis |
C0036866 | Those characteristics that distinguish one SEX from the other. The primary sex characteristics are the OVARIES and TESTES and their related hormones. Secondary sex characteristics are those which are masculine or feminine but not directly related to reproduction. | Characteristic, Sex|Sex Characteristic|Difference, Sex|Dimorphisms, Sexual|Sex Differences|Sexual Dimorphisms|sex difference|sex differences|sexual dimorphism (noncellular)|Dimorphism, Sexual|Dimorphism, Sex|Sex differences|gender differences|Sex Dimorphism|Sex Difference|Sexual Dimorphism|Dimorphisms, Sex|gender difference|Sex Dimorphisms|sex characteristics|Sex Characteristics|Differences, Sex|Characteristics, Sex | Sex Characteristics |
C0085084 | Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089) | motor neuron diseases|Motor Neuron Diseases and Syndromes|MOTOR SYSTEM DISEASE|Neuron Diseases, Motor|Motor neuron disease, NOS|degenerative motor system disorder|Motor System Diseases|Motor Neuron Diseases|MND - Motor neurone disease|disease motor neurons|Neuron Disease, Motor|Motor neuron disease or syndrome|Motor neurons--Diseases|MOTOR NEURON DISEASE|motor neuron disease|degenerative motor system disease|disease motor neuron|disease motor neurones|MOTOR NEURON DISEASES|Motor neuron disease (disorder)|Motor neuron disease|Motor neurone disease|motor neurone disease|Motor System Disease|disease motor neurone | Motor Neuron Disease |
C0002395 | A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) | Alzheimer's disease, NOS|Alzheimer Type Senile Dementia|alzheimer's disease|SENILE DEMENTIA OF THE ALZHEIMER TYPE|Alzheimer Dementias|ALZHEIMER DISEASE|alzheimers dementia|Alzheimer's Dementia|AD - Alzheimer's disease|ALZHEIMER'S DISEASE|Dementia of the Alzheimer's type|Alzheimer Syndrome|SDAT|Alzheimer Type Dementia (ATD)|simple senile dementia|Senile Dementia|Alzheimer Sclerosis|Alzheimer dementia|dats|senile dementia|Alzheimer Type Dementia|Alzheimer disease|Alzheimer Disease|Primary Senile Degenerative Dementia|Dementia, Senile|alzheimer diseases|alzheimers disease|Dementias, Alzheimer|Senile Dementia, Alzheimer Type|dementia alzheimers|Dementia, Primary Senile Degenerative|Alzheimer's disease|Alzheimer's disease (disorder)|alzheimer's diseases|Alzheimer Dementia|DAT|Dementia, Alzheimer-Type (ATD)|Sclerosis, Alzheimer|Dementia, Alzheimer|DEMENTIA OF THE ALZHEIMER TYPE|AD|Alzheimer's Disease|Dementia, Alzheimer Type|Alzheimer-Type Dementia (ATD)|Alzheimers Disease | Alzheimer's Disease |
C0243076 | null | antagonists | antagonists |
C0037657 | Insulin-like polypeptides made by the liver and some fibroblasts and released into the blood when stimulated by SOMATOTROPIN. They cause sulfate incorporation into collagen, RNA, and DNA synthesis, which are prerequisites to cell division and growth of the organism. | Somatomedin|Insulin-Like Growth Factors|Insulin-Like Growth Factor|Factor, Sulfation|IGF|Somatomedins|Somatomedin-containing product|Factors, Insulin-Like Growth|Somatomedin (substance)|somatomedins|insulin like growth factors|Sulfation Factor|Insulin-like growth peptide|insulin-like growth factor|Somatomedin preparation|Product containing somatomedin (medicinal product)|insulin like growth factor|insulin-like growth factors|somatomedin|Insulin-like growth factor|Insulin Like Growth Factors|Growth Factors, Insulin-Like|insulinlike growth factor|factor growth insulin-like|Somatomedin, NOS | Somatomedins |
C0037657 | Insulin-like polypeptides made by the liver and some fibroblasts and released into the blood when stimulated by SOMATOTROPIN. They cause sulfate incorporation into collagen, RNA, and DNA synthesis, which are prerequisites to cell division and growth of the organism. | Somatomedin|Insulin-Like Growth Factors|Insulin-Like Growth Factor|Factor, Sulfation|IGF|Somatomedins|Somatomedin-containing product|Factors, Insulin-Like Growth|Somatomedin (substance)|somatomedins|insulin like growth factors|Sulfation Factor|Insulin-like growth peptide|insulin-like growth factor|Somatomedin preparation|Product containing somatomedin (medicinal product)|insulin like growth factor|insulin-like growth factors|somatomedin|Insulin-like growth factor|Insulin Like Growth Factors|Growth Factors, Insulin-Like|insulinlike growth factor|factor growth insulin-like|Somatomedin, NOS | Somatomedins |
C0037668 | A peptide of 44 amino acids in most species that stimulates the release and synthesis of GROWTH HORMONE. GHRF (or GRF) is synthesized by neurons in the ARCUATE NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, GHRF stimulates GH release by the SOMATOTROPHS in the PITUITARY GLAND. | srf|Growth hormone releasing factor|growth hormone-releasing hormone|somatocrinin|GRF - Growth hormone releasing factor|growth hormone-releasing hormone (GHRH)|Somatotropin Releasing Factor 44|Growth Hormone Releasing Factor|Growth Hormone-Releasing Factor|Growth Hormone Releasing Hormone|GHRH - Growth hormone releasing hormone|GRF 1-44|growth hormone releasing factor|Somatotropin releasing hormone|SRF preparation|Growth Hormone-Releasing Factor 44|Somatotropin releasing factor-containing product|ghrh|GRF|somatotropin-releasing factor (SRF)|Somatotropin-releasing factor|Somatoliberin|Somatotropin releasing factor preparation|GRH|Somatotropin releasing factor (substance)|Growth Hormone Releasing Factor 44|Somatotropin releasing factor|Somatotropin-Releasing Factor 44|Growth Hormone-Releasing Hormone|somatotropin RH|growth hormone RH|Somatotropin releasing factor (SRF)|Growth hormone releasing hormone|Somatocrinin|growth hormone releasing hormone|SRF|Somatotropin Releasing Hormone|Somatotropin-Releasing Hormone|Product containing somatotropin releasing factor (product)|GHRH|GHRH 1-44 | Somatotropin-Releasing Hormone |
C1611640 | <p>A manufactured material (player) that is used for its therapeutic properties. The manufacturer is the scoper.</p> | Therapeutic agent, NOS|therapeutic agent|therapeutic agents | Therapeutic agent (substance) |
C0243071 | A synthetic chemical which structurally or functionally resembles a naturally occurring compound. | analog|Analog|analogs|Analogue | Analog |
C0006625 | General ill health, malnutrition, and weight loss, usually associated with chronic disease. | Wasting|cachexia|cachectic|Cachexia, NOS|CACHEXIA|Cachectic|cachexia (weight loss)|CACHECTIC|Cachexia|Wasting syndrome|Cachexia (finding)|General body deterioration | Cachexia |
C0032008 | The anterior glandular lobe of the pituitary gland, also known as the adenohypophysis. It secretes the ADENOHYPOPHYSEAL HORMONES that regulate vital functions such as GROWTH; METABOLISM; and REPRODUCTION. | Anterior, Lobus|Anterior Lobe of Pituitary|Pars Distalis of Pituitary|Glands, Anterior Pituitary|anterior gland pituitary|Anterior lobe of pituitary gland|Lobus Anterior|pituitary anterior lobe|Pituitary Anterior Lobe|Pituitary anterior lobe|Anterior Lobe of the Pituitary Gland|Pituitary gland, anterior lobe|Pituitary Glands, Anterior|Anterior lobe (hypophysis)|Anterior lobe of pituitary|Lobus Anteriors|anterior pituitary gland|Pituitary Pars Distalis|Anterior Pituitary Gland|Pituitary Gland, Anterior|Anterior lobe of hypophysis|Adenohypophysis structure (body structure)|Adenohypophysis|adenohypophysis|Lobus anterior hypophysis|Pars Anterior Pituitary Gland|anterior lobe pituitary|anterior lobe (pituitary)|Adenohypophysis structure|Anterior Pituitary Glands|Anteriors, Lobus|Lobus anterior (Glandula pituitaria)|Adenohypophyses|Anterior Lobe of Pituitary Gland|Gland, Anterior Pituitary | Pituitary Gland, Anterior |
C0085080 | CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. | cho cells|Chinese hamster ovary cell|Chinese Hamster Ovary Cell|CHO|cho cell|CHO Cells|cells chinese hamster ovary|CHO Cell|Cell, CHO|Cells, CHO|CHO cell | Chinese Hamster Ovary Cell |
C0003695 | An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. | 5, 8, 11, 14-Eicosatetraenoic acid|arachidonic acid|(all-Z)-5,8,11,14-Eicosatetraenoic acid|Eicosatetraenoic acid|acid arachidonic|Arachidonic Acid|vitamin F|5,8,11,14-eicosatetraenoic acid|vitamin f|Vitamin F|Arachidonic acid (substance)|Fatty Acid 20:4 n-6|ARACHIDONIC ACID|5,8,11,14-Eicosatetraenoic acid, (all-Z)-|All-cis-icosa-5,8,11,14-tetraenoic acid|(all-Z)-5,8,11,14-Eicosatetraenoic Acid|5,8,11,14-Eicosatetraenoic acid|Arachidonic acid|AA - arachidonic acid | arachidonic acid |
C0033554 | A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. | prostaglandin|prostanoid|PG|Prostaglandin (substance)|prostanoids|PG - Prostaglandin|PROSTAGLANDINS|Prostaglandin, NOS|prostaglandins|Product containing prostaglandin (product)|Prostanoids|Prostaglandins|Prostaglandin|Prostaglandin-containing product|Prostanoid|Prostanoid (substance) | Prostaglandins |
C0040061 | Physiologically active compounds found in many organs of the body. They are formed in vivo from the prostaglandin endoperoxides and cause platelet aggregation, contraction of arteries, and other biological effects. Thromboxanes are important mediators of the actions of polyunsaturated fatty acids transformed by cyclooxygenase. | thromboxanes|Thromboxane (substance)|Thromboxane, NOS|Thromboxanes|thromboxane|Thromboxane | Thromboxanes |
C0230770 | The lipid bilayer surrounding the endoplasmic reticulum. [GOC:mah] | Endoplasmic reticulum, membrane|Wall of endoplasmic reticulum|ER membrane|Membrane of endoplasmic reticulum|Endoplasmic reticulum wall|endoplasmic reticulum membrane|Endoplasmic reticulum, membrane (cell structure)|Endoplasmic reticulum, NOS, membrane | Endoplasmic reticulum, membrane |
C0544980 | null | Cell membrane receptor site | Plasma membrane receptor site |
C0026227 | null | Receptors, MIT|MIT Receptors|Monoiodotyrosine Receptors | Receptors, Monoiodotyrosine |
C0026227 | null | Receptors, MIT|MIT Receptors|Monoiodotyrosine Receptors | Receptors, Monoiodotyrosine |
C0026227 | null | Receptors, MIT|MIT Receptors|Monoiodotyrosine Receptors | Receptors, Monoiodotyrosine |
C0006556 | Single-stranded complementary DNA synthesized from an RNA template by the action of RNA-dependent DNA polymerase. cDNA (i.e., complementary DNA, not circular DNA, not C-DNA) is used in a variety of molecular cloning experiments as well as serving as a specific hybridization probe. | cdna|Complementary DNA|Complementary deoxyribonucleic acid|cDNA|complementary DNA|complementary DNA (cDNA)|copies dna|Copy DNA|complementary dna|Complementary deoxyribonucleic acid (substance) | DNA, Complementary |
C0034069 | A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. | lung cirrhosis|Fibrosis, Pulmonary|Pulmonary Fibrosis|Cirrhosis of lung, NOS|Fibrosis of lung, NOS|PULMONARY FIBROSIS|Cirrhosis of lung|lung fibrosis|Lung fibrosis|pulmonary fibrosis|Fibroses, Pulmonary|pulmonary fibroses|Pulmonary Interstitial Fibrosis|FIBROSIS PULMONARY|Pulmonary Fibroses|Fibrosis of lung (disorder)|fibrosis lungs|FIBROSIS LUNG|Pulmonary fibrosis|IPF|fibrosis lung|LUNG FIBROSIS|Fibrosis of lung|cirrhosis lung|fibrosis of lung|fibrosis pulmonary | Pulmonary Fibrosis |
C0876768 | a kind of nonsteroidal anti-inflammatory drugs | vioxx|Vioxx | Vioxx Dolor |
C1515119 | Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body. | Systemic Therapy|systemic therapy | Systemic Therapy |
C0011684 | Drugs designed and synthesized, often for illegal street use, by modification of existing drug structures (e.g., amphetamines). Of special interest are MPTP (a reverse ester of meperidine), MDA (3,4-methylenedioxyamphetamine), and MDMA (3,4-methylenedioxymethamphetamine). Many drugs act on the aminergic system, the physiologically active biogenic amines. | Customized Drugs|Designer drugs|Drugs, Designer|designer drug|designer drugs|Drugs, Customized | Designer Drugs |
C0005522 | Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay. | Biological Products|Products, Biological|biological products|Biologic Products | Biological Products |
C1524094 | null | Recombinant Cytokine|Cytokines | Recombinant Cytokines |
C0027410 | Agents inhibiting the effect of narcotics on the central nervous system. | Receptor Antagonists, Opioid|opioid antagonists|Narcotic Antagonists|Substance with opioid receptor antagonist mechanism of action|Opioid Receptor Antagonists|Antagonists, Opioid Receptor|narcotic antagonist|opioid antagonist|Narcotic antagonists|Opioid receptor antagonist|Opioid Antagonists|Product containing opioid receptor antagonist (product)|opiate antagonists|Opiate antagonist, NOS|Opiate Antagonist|Substance with opioid receptor antagonist mechanism of action (substance)|OPIATE ANTAGONISTS|Opioid receptor antagonist-containing product|Narcotic Antagonist|opiate antagonist|Antagonists, Narcotic|Opioid Antagonist|narcotic antagonists|Antagonists, Opioid | Narcotic Antagonists |
C0022131 | Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. | islets of Langerhans|islands of langerhans|Langerhans Islands|Pancreatic islets set|Islands of Langerhans|islets langerhans of|pancreatic islets|Endocrine pancreas|Islet, Pancreatic|Nesidioblast|islets of langerhans|PANCREAS, ENDOCRINE|endocrine pancreas|Human Pancreatic Islet Cells|ENDOCRINE PANCREAS|Cells, Islet|Endocrine pancreatic structure|islet pancreatic|cell islet|Islet Cells|cells islets|islets langerhan|Endocrine Pancreas|Set of pancreatic islets|Pancreatic Islet|islands langerhans|islet langerhans|langerhans islets|Pars endocrina pancreatis|Endocrine pancreatic structure (body structure)|pancreas endocrine|Pancreatic Islets|Langerhans Islets|Islets, Pancreatic|Pancreas, Endocrine|islet of langerhans|Islet of Langerhans|Pancreatic islets|Pancreatic islet|cells islet|Pancreatic insula|Insulae pancreaticae|cell islets|Islet Cell|Pars Endocrina Pancreatis|Islets of Langerhans|pancreatic islet|Islet cell|islets langerhans|islet langerhan|islet cells|Nesidioblasts|Cell, Islet|islet cell | Islets of Langerhans |
C0205752 | family of endogenous compounds, including peptides, which mimic the action of opiates on neurons, lymphocytes, and other cells; involved in pain suppression and other neurobehavioral phenomena; for opiate drugs use OPIATE ALKALOID. | Endogenous Opiates|Endogenous Opioids|endorphin|endogenous opiates|Opiates, Endogenous|endogenous opioid|endogenous opioids|endogenous opiate | Endogenous Opiates |
C0242402 | A substance used to treat moderate to severe pain. Opioids are like opiates, such as morphine and codeine, but are not made from opium. Opioids bind to opioid receptors in the central nervous system. An opioid is a type of alkaloid. | Opioid|Opioid receptor agonist|OPIATE AGONISTS|opiate agonists|Opiate agonist, NOS|opiate agonist|opioids in any form|Substance with opioid receptor agonist mechanism of action (substance)|Substance with opioid receptor agonist mechanism of action|opioids|opioid product|opiates in any form|opioid|Opioids | Opioids |
C0032460 | A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading. | Ovarian Degeneration, Sclerocystic|Polycystic ovary disease|Stein-Leventhal syndrome|BILATERAL POLYCYSTIC OVARIAN SYNDROME|Sclerocystic Ovary Syndrome|polycystic ovarian syndrome|Stein Leventhal Syndrome|STEIN-LEVENTHAL SYNDROME|Multicystic ovaries|stein-leventhal syndrome|Polycystic ovarian disease|polycystic ovary syndrome (PCOS)|Polycystic ovary syndrome (disorder)|Ovary Syndrome, Polycystic|polycystic ovary syndrome|stein leventhal syndrome|Stein Lenventhal syndrome|polycystic ovaries|POYCYSTIC OVARIAN SYNDROME|Polycystic ovary syndrome|ovarian hyperthecosis|Polycystic Ovary Syndrome|PCOS- polycystic ovary syndrome|ovarian polycystic disease|POLYCYSTIC OVARY SYNDROME 1|polycystic ovary disease|POLYCYSTIC OVARY DISEASE|Cystic disease of ovary|PCOS|POLYCYSTIC OVARIAN SYNDROME|Ovarian Syndrome, Polycystic|ovary polycystic|Syndrome, Stein-Leventhal|disease ovarian polycystic|Stein-Leventhal ovaries|HYPERTHECOSIS, OVARIAN|Syndrome, Polycystic Ovary|Polycystic Ovary Syndrome 1|ovaries polycystic|Polycystic ovaries|Polycystic ovary (disorder)|PCO|PCO1|Cystic disease of ovaries|Polycystic Ovarian Disease|polycystic ovary disorder|multicystic ovaries|disease ovary polycystic|Stein-Leventhal Syndrome|Polycystic Ovarian Syndrome|PCOS1|sclerocystic ovarian disease|polycystic ovary|STEIN LEVENTHAL SYNDROME|Polycystic ovary|Sclerocystic Ovarian Degeneration|diseases ovary polycystic|SCLEROCYSTIC OVARIAN DISEASE|polycystic ovarian disease | Polycystic Ovary Syndrome |
C0029967 | Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum. | Ovulation Induction|of ovulation induction|Ovulation--Induction|ovulation induction|Induction of ovulation|Ovulation induction (procedure)|ovary hyperstimulation|hyperstimulation ovary|induction ovulation|induction of ovulation|Ovulation induction|Hyperstimulation of ovary | Ovulation Induction |
C0027360 | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Product containing naltrexone (medicinal product)|Naltrexon|naltrexone|Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-|Naltrexone|Naltrexonum|17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one|Naltrexona|N-Cyclopropylmethyl-14-hydroxydihydromorphinone|NALTREXONE|Naltrexone (substance)|Naltrexone-containing product|N-Cyclopropylmethylnoroxymorphone|17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one | naltrexone |
C0036884 | A class of steroid hormones that specifically binds to and activates androgen, progesterone or estrogen receptors. Sex steroids activate various signaling pathways involved in the development and maintenance of secondary sexual characteristics, reproductive processes, blood salt balance, response to stress, neuronal function and a number of metabolic processes. | Sex Steroid|hormones sex|Sex Steroid Hormones|Sex Hormone|Hormones, Sex Steroid|Sex Steroid Hormone|sex hormone|gonadal steroid hormone|Sex Hormones|gonadal steroids|sex hormones|Hormones, Gonadal Steroid|Hormones, Sex|Steroid Hormones, Sex|Steroid Hormones, Gonadal | Gonadal Steroid Hormones |
C0027358 | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. | NALOXONE|Naloxone-containing product|Naloxone (substance)|naloxone|Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-|17-allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one|1-N-Allyl-14-hydroxynordihydromorphinone|(-)-naloxone|Naloxone|(-)-Naloxone|Product containing naloxone (medicinal product)|Nalossone|Naloxonum|Naloxona | naloxone |
C0027360 | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Product containing naltrexone (medicinal product)|Naltrexon|naltrexone|Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-|Naltrexone|Naltrexonum|17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one|Naltrexona|N-Cyclopropylmethyl-14-hydroxydihydromorphinone|NALTREXONE|Naltrexone (substance)|Naltrexone-containing product|N-Cyclopropylmethylnoroxymorphone|17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one | naltrexone |
C0020459 | A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS. | Hyperinsulinism|Hyperinsulinaemia|Hyperinsulinism (disorder)|HYPERINSULINEMIA|Hyperinsulinism syndrome|hyperinsulinemia|Hyperinsulinism, NOS|increased insulin|Hyperinsulinemia|hyperinsulism|INSULIN INCREASE|Elevated insulin level|increasing insulin|Hyperinsulinism NOS|high insulin|Elevated insulin levels|insulin high|hyperinsulinism|hyperinsulinaemia | Hyperinsulinism |
C0010760 | A multisubunit enzyme complex containing CYTOCHROME A GROUP; CYTOCHROME A3; two copper atoms; and 13 different protein subunits. It is the terminal oxidase complex of the RESPIRATORY CHAIN and collects electrons that are transferred from the reduced CYTOCHROME C GROUP and donates them to molecular OXYGEN, which is then reduced to water. The redox reaction is simultaneously coupled to the transport of PROTONS across the inner mitochondrial membrane. | Cytochrome-c oxidase|cytochrome oxidase c|Cytochrome Oxidase|complex iv|Cytochrome-c Oxidase|cytochrome oxidase|Cytochrome c oxidase|Ferrocytochrome c Oxygen Oxidoreductase|Oxidase, Cytochrome-c|Ferricytochrome-c:oxygen oxidoreductase|Cytochrome-c Oxidase (Complex IV)|Oxidase, Cytochrome|Cytochrome oxidase|Cytochrome C Oxidase|complex IV|Cytochrome c Oxidase|Cytochrome c oxidase (substance)|Electron Transport Complex IV|Complex IV|cytochrome c oxidase|Electron Transport Chain Complex IV | CYTOCHROME C OXIDASE |
C0682538 | null | null | intact cell |
C0064859 | null | null | leupeptin acid synthetase |
C0028589 | Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. | Proteins, Nuclear|Nuclear Proteins|Nuclear proteins|Nuclear Protein|nuclear protein | Nuclear Proteins |
C0028606 | High molecular weight polymers containing a mixture of purine and pyrimidine nucleotides chained together by ribose or deoxyribose linkages. | acids nucleic|Nucleic acids|Nucleic acid, NOS|nucleic acid|Nucleic acid (substance)|nucleic acids|Acids, Nucleic|Nucleic acid|Nucleic Acids|Nucleic Acid|acid nucleic|NUCLEIC ACID SUBSTANCE | Nucleic Acids |
C0021102 | A substance or object that is put in the body as a prosthesis, or for treatment or diagnosis. | Implant, device (physical object)|Implant|Implanted|Implantable|Implant, NOS|implant|implants|Implant, device|implant prosthesis|Implants | Implants |
C0018592 | Highly pleasant emotion characterized by outward manifestations of gratification; joy. | good mood|happiness|joys|happy|Cheerful mood|Happy|joy|Happiness|Good mood|joy, festive|High spirits|Happinesses|Cheerful mood (finding)|Bright in mood|Happy mood|In good spirits | Happiness |
C0243042 | The endogenous compounds that mediate inflammation (AUTACOIDS) and related exogenous compounds including the synthetic prostaglandins (PROSTAGLANDINS, SYNTHETIC). | Mediator of inflammation, NOS|Inflammation--Mediators|MEDIATORS OF INFLAMMATION|Mediator of inflammation|Mediators, Inflammation|Mediator of inflammation (substance)|inflammation mediators|Mediators of Inflammation | Inflammation Mediators |
C0965644 | Hypoxia-inducible factor 1, alpha subunit is a basic helix-loop-helix transcription factor that is regulated by OXYGEN availability and is targeted for degradation by VHL TUMOR SUPPRESSOR PROTEIN. | Hypoxia-Inducible Factor 1, alpha Subunit|Hypoxia Inducible Factor 1, alpha Subunit | HIF1alpha protein |
C0082529 | A 44-kDa extracellular signal-regulated MAP kinase that may play a role the initiation and regulation of MEIOSIS; MITOSIS; and postmitotic functions in differentiated cells. It phosphorylates a number of TRANSCRIPTION FACTORS; and MICROTUBULE-ASSOCIATED PROTEINS. | Meiosis-Activated Myelin Basic Protein Kinase p44(mpk)|mitogen-activated protein kinase-3 (MAPK3)|Protein-Serine-Threonine Kinase p44(mpk)|MAPK3 Mitogen-Activated Protein Kinase|Kinase, ERK1|p44mpk, PSTkinase|Mitogen Activated Protein Kinase 3|MAPK3 Mitogen Activated Protein Kinase|PSTkinase p44mpk|Microtubule-Associated Protein-2 Kinase|erk 1|erk1|ERK 1|Extracellular Signal Regulated Kinase 1|Kinase, Microtubule-Associated Protein-2|Extracellular Signal-Regulated Kinase 1|extracellular signal-regulated kinases 1 (ERK1)|Microtubule Associated Protein 2 Kinase|p44 MAPK|ERK1 Kinase|Mitogen-Activated Protein Kinase 3 | Mitogen-Activated Protein Kinase 3 |
C1150462 | Catalysis of the reaction: ATP + creatine = N-phosphocreatine + ADP + 2 H(+). [EC:2.7.3.2, RHEA:17157] | MB-CK|CKMiMi|CK-MB|creatine phosphotransferase activity|CK-MM|Mi-CK|MM-CK|creatine kinase activity|phosphocreatine kinase activity|ATP:creatine N-phosphotransferase activity|ATP:creatine phosphotransferase activity|creatine phosphokinase activity|adenosine triphosphate-creatine transphosphorylase activity|CK-BB|CK|BB-CK | creatine kinase activity |
C0040861 | The sorting out and classification of patients or casualties to determine priority of need and proper place of treatment. | Triages|Triage (Medicine)|Triage|triage|Triage (procedure) | Triage |
C0340107 | null | Uremic pneumonitis|Uraemic lung|Uremic lung (disorder)|Uremic pneumonia|Uremic pulmonary edema|uremic lung|Uraemic pulmonary oedema|lung uremic|Uraemic pneumonitis|Uraemic pneumonia | Uremic lung |
C0264936 | null | Hypertension, pulmonary, secondary|Pulmonary hypertension, secondary|Secondary pulmonary hypertension (disorder)|hypertension pulmonary secondary|pulmonary hypertension secondary|secondary pulmonary hypertension|PULMONARY HYPERTENSION SECONDARY|Secondary pulmonary hypertension | Secondary pulmonary hypertension |
C0152171 | Increased blood pressure in the arteries of the lungs; the etiology is unknown. | Primary pulmonary hypertension|primary pulmonary hypertension|Primary Pulmonary Hypertension|Idiopathic Pulmonary Arterial Hypertension|Essential pulmonary hypertension|Pulmonary hypertension, idiopathic|Pulmonary hypertension, primary|pulmonary primary hypertension|PULMONARY HYPERTENSION PRIMARY|hypertension primary pulmonary|HYPERTENSION, PULMONARY, PRIMARY|Pulmonary hypertension, essential|Idiopathic Pulmonary Hypertension|Hypertension, pulmonary, primary|Idiopathic pulmonary hypertension|IPAH | Idiopathic pulmonary hypertension |
C0000975 | A form of acetic acid (an acid found in vinegar). | Acetate|Ethanoate|Acetate (substance)|ACETATE|acetate|Ethanoat | acetate |
C0005367 | Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity. | hco3|Bicarbonate|Carbonates, Hydrogen|bicarbonates|Bicarbonate, NOS|Bicarbonate (HCO3)|Bicarbonates|Hydrogen Carbonates|HCO3 - Bicarbonate|Bicarbonate (substance)|BICARBONATES|HCO3|bicarbonate | Bicarbonates |
C0227349 | null | colon mucosa|Colonic mucosa|Colonic mucous membrane structure|Colon mucosa|colonic mucosa|Colonic mucous membrane|Colonic mucous membrane structure (body structure)|mucosa colon|Mucosa of colon | Colonic mucous membrane |
C0333961 | null | Hypertrophy, compensatory|Secondary hypertrophy (morphologic abnormality)|Compensatory hypertrophy|Hypertrophy, secondary|Secondary hypertrophy | Secondary hypertrophy |
C1514845 | Tissue composed of the renal cortex and the renal medulla. The basic functional unit of renal tissue is the nephron. | Renal Tissue | Renal Tissue |
C0034716 | A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. | Wistar Rats|Wistar rat|wistar rat|Wistar rat (organism)|wistar rats | Rats, Wistar |
C0043481 | A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with ANEMIA, short stature, HYPOGONADISM, impaired WOUND HEALING, and geophagia. It is known by the symbol Zn. | Zinc|zn|Zinc, elemental|Zinc (substance)|Zinc, NOS|Zn element|ZINC|Zn - Zinc|zinc|Zn|Zincum metallicum|Zinc-containing product|Product containing zinc (medicinal product) | zinc |
C0027695 | Excision of kidney. | Nephrectomies|KIDNEY: EXCISIONS|Nephrectomy|NEPHRECTOMY|Kidney excision|Kidney excision (procedure)|nephrectomies|nephrectomy|nephrectomy procedure|Nephrectomy, NOS | Nephrectomy |
C0028128 | A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. | endothelial cell derived relaxing factor|óxido de nitrógeno(II)|Vasodilator, Endogenous Nitrate|óxido nítrico|Endogenous Nitrate Vasodilator|Oxyde nitrique|nitric oxides|Nitric oxide-containing product|Oxide, Nitric|Stickstoff(II)-oxid|endothelium-derived relaxing factor|Product containing nitric oxide (medicinal product)|Nitrogen monoxide|edrf|Monoxide, Mononitrogen|Nitric oxide|NITRIC OXIDE|EDRF|nitric oxide|nitrogen protoxide|Nitric Oxide, Endothelium Derived|Stickstoffmonoxid|Nitrate Vasodilator, Endogenous|Nitric oxide (substance)|Monoxide, Nitrogen|Nitrogen Oxide|Nitrogen oxide (NO)|Endothelium-Derived Relaxing Factor|Monoxyde d'azote|Nitric Oxide|Mononitrogen Monoxide|Nitrogen Monoxide|Nitric Oxide, Endothelium-Derived|Endothelium-Derived Nitric Oxide|Monóxido de nitrógeno|NO - Nitric oxide|Nitrosyl|Mononitrogen monoxide|NO|Nitric oxide gas|Nitrogen monooxide|Oxyde azotique | nitric oxide |
C0876928 | Used to describe an individual who is unsure of their sexual orientation. | questioning | Questioning |
C0149779 | The conversion of mental experiences or states into physical symptoms. | SOMATIZATION|somatization|Somatization | Somatization |
C0003467 | Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS. | anxiety|anxiety reaction|Anxiety (finding)|Anxiousness|angst|unfocused anxiety|Anxious|Anxious behavior|ANXIETY|anxieties|Feeling anxious|Anxiety reaction|Anxiety Reaction|anxious|anxiousness|Anxiety|ANXIETY REACTION|Excessive, persistent worry and fear|REACTION ANXIETY | Anxiety |
C0424639 | The height of a person while standing. | length growth|growth height|Height AND/OR growth measure|Height / growth measure|Height / growth measure (observable entity)|stature|Stature|height growth | Height / growth measure |
C0006629 | A dead body, usually a human body. | Cadaver (substance)|cadaver|corpse|Cadavers|Cadaver|cadavers|Corpses|corpses|Corpse | Cadaver |
C0018378 | An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314) | Landry's paralysis|Guillain-Barré syndrome|Landry-Guillain-Barré syndrome|Guillain-Barré Syndromes|Guillain-Barre Syndrome|Landry-Guillain-Barre Syndrome|Syndrome, Guillain-Barre|GUILLAIN BARRE SYNDROME|Guillain-Barré Syndrome|Guillaine-Barre Syndrome|SYNDROME GUILLAIN-BARRE|GUILLAIN-BARRE DISEASE|Guillain Barré Syndrome|Guillain Barre syndrome|GUILLAIN BARRE DISEASE|Guillain-Barre syndrome|LANDRY PARALYSIS|guillain-barre disease|Syndrome, Guillain-Barré|guillain-barre syndrome|Guillaine Barre Syndrome|GULLIAN BARRE SYNDROME|GBS|GUILLAIN-BARRE SYNDROME|Syndrome, Landry-Guillain-Barre|guillain barre syndrome|Syndromes, Guillain-Barré|Landry Guillain Barre Syndrome|Guillain Barre Syndrome|Landry-Guillain-Barre syndrome|Syndrome, Guillaine-Barre|guillain-barre syndrome (GBS)|Guillain-Barré syndrome (disorder)|landry's paralysis | Guillain-Barre Syndrome |
C0035168 | Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed) | research|inquiry|Research | research |
C0678222 | Cancer that forms in tissues of the breast, usually the ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). It occurs in both men and women, although male breast cancer is rare. | CARCINOMA OF BREAST|Cancer of Breast|Carcinoma of the Breast|Breast Cancer|BREAST CANCER, CARCINOMA|breast cancer diagnosis|breast carcinomas|Cancer, Breast|Carcinoma of Breast|Breast Carcinoma|Breast cancer|Carcinoma of breast (disorder)|CARCINOMA BREAST|Breast cancer, NOS|Breast carcinoma|BREAST, CARCINOMA|Carcinoma of breast|CA - Carcinoma of breast|Breast Carcinomas|breast carcinoma|breast cancer|Carcinoma, Breast|Cancer of the Breast|BREAST CARCINOMA|Mammary Carcinoma|Carcinomas, Breast|carcinoma of breast | Breast Carcinoma |
C0596473 | Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME. | Diagnosis, Early|diagnosis early|early detection|diagnose early|Early Detection|early diagnoses|detection early|early diagnosis | Early Diagnosis |
C0442867 | null | diseases malignant|disease malignant | malignant disease |
C1520142 | A diagnostic technique which produces a two- dimensional image of a desired anatomical structure or region with the use of radionuclides. | Whole-Body Scintigraphy|WBS|whole-body scintigraphy | Whole-Body Scintigraphy |
C0027627 | The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. | tumour metastasis|metastasized|metastatic neoplasm|metastasis|metastatic tumour|spreading of tumor|Tumor Cell Migration|secondary tumors|Metastasis|metastatic tumors|metastatic tumor|metastatic disease|secondary cancer|cancer secondary|metastatic tumours|Metastasize|Metastases, Neoplasm|Neoplasm Metastasis|cancers secondary|Metastases|secondary malignancies|Metastasis, Neoplasm|metastatic cancer|metastasize|metastases|metastasis tumor|secondaries|tumor metastasis|secondary|spreading of cancer (tumor)|Neoplasm Metastases|secondary tumor | Neoplasm Metastasis |
C0020456 | Abnormally high BLOOD GLUCOSE level. | Hyperglycemic disorder|Blood Glucose, High|High Blood Sugar|Hyperglycemia (disorder)|hyperglycaemia|elevated glucose|Hyperglycaemia, NOS|HYPERGLYCAEMIA|Hyperglycemia|Hyperglycaemic disorder|Hyperglycemias|hyperglycemia|Hyperglycemic disorder (disorder)|high blood sugar|elevated blood sugar|HYPERGLYCEMIA|High Blood Glucose|Hyperglycemia, NOS|high blood sugar level|High blood glucose|Hyperglycaemia|High blood sugar|Hyperglycemia NOS|Elevated Blood Glucose|Glucose, High Blood | Hyperglycemia |
C0240066 | Subnormal concentrations of iron resulting from low iron intake, inefficient iron absorption in the gastrointestinal tract, or increased iron loss. | Iron deficiency (disorder)|Iron Deficiency|IRON DEFICIENCY|Iron deficiency|iron deficiencies|iron deficiency|Iron deficiency, NOS | Iron deficiency |
C0002871 | A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. | Anemia, NOS|anemia|Anemias|ANEMIA|Anemia (disorder)|Anaemia, NOS|anaemia|Anemia; unspecified|Anemia, unspecified|anaemias|Anemia|ANAEMIA|anemias|Anaemia | Anemia |
C0359086 | null | hypoglycemics oral|oral hypoglycemic agent|oral hypoglycemic agents|agents hypoglycemics oral|agent hypoglycemic oral | oral hypoglycemic |
C0021044 | Histochemical localization of immunoreactive substances using labeled antibodies as reagents. | Immunohistochemistry technique|Immunohistochemistry technique (qualifier value)|Immunohistochemistry Staining Method|immunohistochemistry staining method|Immunohistochemical Test|Immunohistochemistry procedure (procedure)|Immunohistochemistry procedure|IHC|Cell/Tissue, Immunohistochemistry|Immunohistochemistry|immunohistochemistry | Immunohistochemistry |
C0010075 | The veins and arteries of the HEART. | Vessels, Coronary|Coronary Vessel|vessel coronary|coronary vessels|Vessel, Coronary|coronary vessel | Coronary Vessels |
C0151814 | Complete blockage of blood flow through one of the CORONARY ARTERIES, usually from CORONARY ATHEROSCLEROSIS. | Occlusions, Coronary|Coronary occlusion|arteries coronary occluded|occlusion coronary|Occlusion, Coronary|CORONARY ARTERY OCCLUSION|OCCLUSION CORONARY ARTERY|Coronary occlusion NOS|Coronary artery occlusion|Coronary artery occluded|OCCLUSION, CORONARY|CORONARY OCCLUSION|Coronary occlusion, NOS|coronary artery occlusion|coronary artery occluded|artery coronary occlusion|coronary occlusion|Coronary occlusion (disorder)|Coronary Occlusions | Coronary Occlusion |
C0240035 | An evaluation of the presence or degree of interstitial fibrosis present in a sample. | Interstitial Fibrosis Assessment|INTSFBRO|Interstitial Fibrosis | Interstitial Fibrosis Assessment |
C0068333 | A synthetic cannabinoid and dibenzopyrane derivative with anti-emetic activity. Although the mechanism of action has not been fully elucidated yet, it has been suggested that nabilone is a highly selective and strong agonist for the cannabinoid receptors CB1 and CB2, both of which are coupled to Gi/o proteins. The CB1 receptors are expressed predominantly in central and peripheral neurons and receptor stimulation has been implicated in the reduction of chemotherapy-induced nausea. | NABILONE|Nabilonum|Nabilone (substance)|Nabilone|nabilone|Nabilona|Nabilon|Nabilone-containing product|3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one|Product containing nabilone (medicinal product) | nabilone |
C0068333 | A synthetic cannabinoid and dibenzopyrane derivative with anti-emetic activity. Although the mechanism of action has not been fully elucidated yet, it has been suggested that nabilone is a highly selective and strong agonist for the cannabinoid receptors CB1 and CB2, both of which are coupled to Gi/o proteins. The CB1 receptors are expressed predominantly in central and peripheral neurons and receptor stimulation has been implicated in the reduction of chemotherapy-induced nausea. | NABILONE|Nabilonum|Nabilone (substance)|Nabilone|nabilone|Nabilona|Nabilon|Nabilone-containing product|3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one|Product containing nabilone (medicinal product) | nabilone |
C0006864 | Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL. | Product containing cannabinoid (product)|Cannabinoid product|cannabinoid|Cannabinoids|Cannabinoid|Cannabinoid (substance)|Product containing cannabinoid|cannabinoids | Cannabinoids |
C0150055 | Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain. | Chronic Pains|Pain, Chronic|Pains, Chronic|Chronic pain (finding)|Chronic pain|Long-lasting pain|Chronic Pain|chronic pain | Chronic pain |
C1267117 | null | Entire vertebral arch joint|Entire zygapophyseal joint|Entire zygapophyseal joint (body structure)|Entire facet joint|Entire zygapophysial joint | Entire zygapophyseal joint |
C0222679 | The bone surface in a joint. | Articular surface of bone|Structure of articular surface of bone|facet|Facet, NOS|Articular Bone Surface|Articular facet, NOS|Facet|articular facet|Articular surface of bone, NOS|Articular facet|facets|Structure of articular surface of bone (body structure) | Structure of articular surface of bone |
C0262655 | Repeated infections of the urinary tract. [HPO:probinson] | Urinary tract infections|Recurrent urinary tract infections|recurrent uti|URINARY TRACT INFECTIONS RECURRENT|Urinary tract infection|URINARY TRACT INFECTION RECURRENT|RECURRENT URINARY INFECTIONS|RECURRENT UTI|Frequent urinary tract infections|Recurrent UTIs|Urinary tract infections, recurrent|Recurrent urinary tract infection|Recurrent UTI - urinary tract infection|recurrent urinary tract infection|Urinary infection|Recurrent urinary tract infection (disorder) | Recurrent urinary tract infection |
C0003874 | null | Acute suppurative arthritis caused by bacteria|Acute suppurative arthritis due to bacteria|Acute suppurative arthritis caused by bacteria (disorder) | Acute suppurative arthritis due to bacteria |
C0006050 | A drug used to treat certain medical conditions. These include severe underarm sweating and severe muscle spasms in the neck and shoulders. OnabotulinumtoxinA is also used to smooth wrinkles on the face. It is being studied in the treatment of pain in patients with skin leiomyomas (benign smooth muscle tumors) and other conditions. It is a form of a toxin made by the bacterium Clostridium botulinum.. | botulinum toxin A|toxin botulinum type a|BOTULINUM TOXIN TYPE A|botulinum toxin type A|Botulinum toxin type A (substance)|botulinum neurotoxin type A|Neurotoxin A, Botulinum|Botulinum toxin A|Clostridium botulinum A Toxin|Botulinum A Toxin|botulinum toxin type|Botulinum A neurotoxin|Botulinum Neurotoxin Type A|Toxin, Botulinum A|botulinum toxin type a|Botulinum Toxins, Type A|DaxibotulinumtoxinA|botulinum A toxin|Botulinum toxin type A-containing product|Botulinum Neurotoxin A|Product containing botulinum toxin type A (medicinal product)|Botulinum Toxin Type A|Toxine botulinique A|Clostridium Botulinum Toxin Type A|Botulinum toxin type A|botulinum a toxin|Toxina botulínica A|Botulinum Toxin A|BTX-A|botulinum toxin a | botulinum toxin type A |
C1328821 | directional growth of or to a tissue in response to an external stimulus. | null | tissue tropism |
C0074406 | null | 1,3-benzodioxol-5-ol|5-hydroxy-1,3-benzodioxole|3,4-methylenedioxyphenol | sesamol |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.